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Abstract
Background
The objective of this study was to evaluate whether the levels of coenzyme Q10 (CoQ10) in
brain tissue of multiple system atrophy (MSA) patients differ from those in elderly controls
and in patients with other neurodegenerative diseases.
Methods
Flash frozen brain tissue of a series of 20 pathologically confirmed MSA patients [9 olivo-
pontocerebellar atrophy (OPCA) type, 6 striatonigral degeneration (SND) type, and 5
mixed type] was used for this study. Elderly controls (n = 37) as well as idiopathic Parkin-
son's disease (n = 7), dementia with Lewy bodies (n = 20), corticobasal degeneration
(n = 15) and cerebellar ataxia (n = 18) patients were used as comparison groups.
CoQ10 was measured in cerebellar and frontal cortex tissue by high performance liquid
chromatography.
Results
We detected a statistically significant decrease (by 3–5%) in the level of CoQ10 in the
cerebellum of MSA cases (P = 0.001), specifically in OPCA (P = 0.001) and mixed cases
(P = 0.005), when compared to controls as well as to other neurodegenerative diseases
[dementia with Lewy bodies (P<0.001), idiopathic Parkinson's disease (P<0.001), cortico-
basal degeneration (P<0.001), and cerebellar ataxia (P = 0.001)].
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Conclusion
Our results suggest that a perturbation in the CoQ10 biosynthetic pathway is associated
with the pathogenesis of MSA but the mechanism behind this finding remains to be
elucidated.
Introduction
Multiple system atrophy (MSA) is a fatal late onset neurodegenerative condition. Clinically,
MSA is characterized by parkinsonism, cerebellar ataxia and autonomic dysfunction. Patholog-
ically, it presents with widespread alpha-synuclein immunoreactive glial cytoplasmic inclusions
and neurodegeneration [1], and can be subdivided into 3 neuropathological subtypes according
to the affected brain regions. These subtypes are: 1) olivopontocerebellar atrophy (OPCA), 2)
striatonigral degeneration (SND), and 3) a combination of the two, referred to as mixed [2].
These subtypes correspond to the clinical subdivision of MSA into MSA-C (OPCA), MSA-P
(SND) and mixed. MSA is often classified as an alpha-synucleinopathy together with idiopathic
Parkinson’s disease (IPD) and Dementia with Lewy bodies (DLB) in view of the intracellular
accumulation of alpha-synuclein. The etiology of MSA is still unknown although a genetic
component has been proposed [3–6].
Coenzyme Q10 (CoQ10) is a lipophilic molecule located in the inner mitochondrial mem-
brane and functions as an electron transporter from complexes I and II to complex III in the
respiratory chain [7]. CoQ10 is the predominant coenzyme Q in humans, has an antioxidant
role, transports electrons in extramitochondrial systems and participates in the regulation of
the mitochondrial transition permeability pore [7].
Complete CoQ10 knockout in mammalian models has been shown to be embryonic lethal
[8, 9]. In humans, disorders of CoQ10 deficiency are subdivided into primary CoQ10 deficien-
cies in which pathogenic mutations occur in the genes required for CoQ10 biosynthesis or sec-
ondary caused by mutations in genes not involved in biosynthesis (reviewed in [10]). The
phenotype of these patients is usually different from the clinical presentation of MSA patients
[11]. CoQ10 deficiencies present as mitochondrial diseases, symptoms including encephalo-
myopathy, ataxia with cerebellar atrophy and can also involve renal failure. The onset of
CoQ10 deficiency generally occurs in childhood, although there are a few cases of onset in
early adulthood [12]. CoQ10 deficiency constitutes a very interesting and potentially treatable
condition with CoQ10 supplements, and is thought to be inherited in an autosomal recessive
fashion.
COQ2 is a gene that encodes for parahydroxybenzoate-polyprenyl transferase, an enzyme
that participates in the synthetic pathway of CoQ10. Through linkage analysis and whole-
genome sequencing, variants in COQ2 have been linked to clinically diagnosed Japanese MSA
patients in a multicenter study. This study also described decreased growth rates in COQ2
mutant yeasts and proposed that variants in the COQ2 gene are a cause of familial MSA and a
risk factor for sporadic MSA [6]. We and other groups have been unable to replicate this
genetic finding so far [13–15]. The authors of that study, by analyzing a small sample group,
suggested decreased levels of CoQ10 in brain tissue of MSA cases (n = 3) in comparison with
controls (n = 3)[6]. In view of this result, we decided to determine the level of CoQ10 in brain
tissue from a large cohort of pathologically confirmed MSA cases and compare these levels to
those of normal controls as well as to patients with other neurodegenerative movement
disorders.
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Materials and Methods
Standard protocol approvals and informed consent
University College London Hospitals (UCLH) ethics committee approved the study (UCLH
ethics approval UG2UPD|04/Q0505/2). Brain tissue was obtained from the Queen Square
Brain Bank (QSBB), UCL and the London Neurodegenerative Diseases Brain Bank, Institute of
Psychiatry, King’s College London, in London (UK), the MRC Sudden Death Brain and Tissue
Bank, in Edinburgh (UK), the IDIBAPS Brain Bank, in Barcelona (Spain), the Human Brain
and Spinal Fluid Resource Center, in Los Angeles (USA), and the Harvard Brain Tissue
Resource Center, in Belmont MA (USA). Written informed consent was obtained from all par-
ticipants. Tissue stored in the QSBB is under a license from the Human Tissue Authority and
has been donated for research according to protocols approved by the NRES Committee Lon-
don-Central.
Subjects
We analyzed the available pathologically confirmed MSA cases (n = 20) and pathologically
normal elderly controls (n = 37). With the purpose of comparing to other alpha-synucleinopa-
thies we also analyzed DLB cases (n = 20) and IPD cases (n = 7) and to compare to a tauopathy
we used corticobasal degeneration (CBD) cases (n = 15). Finally, to compare to other degenera-
tive diseases that affect the cerebellum we decided to include cerebellar ataxia (CRB_ATX)
cases (n = 18). A description of the cases used in this study is given in Table 1 [16]. We used
Table 1. Characterization of the samples included in this study.
Diagnosis groups MSA all MSA-OPCA MSA-MIX MSA-SND CBD DLB IPD CRB_ATXa Controls
Demographic features
Number of cases 20 9 5 6 15 20 7 18 37
Cases with CRBL
available
20 9 5 6 15 20 7 18 37
Cases with FCTX
available
20 9 5 6 0 20 7 18 28
Gender (% of
female)
70% 56% 80% 83% 40% 25% 14% 50% 46%
Mean age at
death, years
(range)
64.55 (51;
74)
64.1 (57; 72) 65.4 (57; 73) 64.5 (51;
74)
69.60 (48;
90)
77.72 (66;
92)
77.86 (65;
84)
59.89 (36;
88)
81.32 (63;
102)
Mean post-mortem
delay, hours
53.44 44.96 67.86 54.14 53.43 21.23 54.89 33.25 15.66
Unadjusted levels of CoQ10 (pmol/mg)
Mean CRBL (±SD) 169.30*
(±49.71)
150.52**
(±29.12)
163.44**
(±73.40)
202.33
(±41.79)
271.18
(±76.21)
288.37
(±133.72)
262.47
(±28.84)
233.08
(±46.97)
241.87
(±57.70)
Mean FCTX (±SD) 260.44
(±70.22)
264.87
(±75.19)
283.98
(±88.91)
234.17
(±44.12)
- 256.94
(±75.20)
276.02
(±71.37)
330.12
(±96.14)
259.39
(±107.09)
*MSA presents significantly lower cerebellar CoQ10 levels when compared to all other diagnosis groups (Tukey test, p  0.002)
**when dividing by disease subgroups, only MSA-OPCA and MSA-Mix show significantly lower levels than controls, CBD, DLB, FRDAa, and IPD (Tukey
test, p  0.02); no other significant differences were observed between groups for CoQ10 levels.
Glossary: MSA = multiple system atrophy; MSA-OPCA = MSA olivopontocerebellar atrophy; MSA-MIX = MSA mixed type; MSA-SND = MSA striatonigral
degeneration; CBD = corticobasal degeneration; DLB = dementia with Lewy bodies; IPD = idiopathic Parkinson’s disease; CRB_ATX = cerebellar ataxia
[aincludes: SCA = spinocerebellar ataxia (n = 9); FRDA = Friedreich's ataxia (n = 5); other ataxias (miscelaneous) (n = 4)]; CRBL = cerebellar cortex;
FCTX = frontal cortex; SD = standard deviation.
doi:10.1371/journal.pone.0149557.t001
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flash frozen brain tissue from these cases and we measured CoQ10 in the cerebellum (cerebel-
lar cortex) and frontal cortex (Brodmann areas 8 or 9). Cerebellum was selected as a severely
affected region in MSA, particularly in OPCA and mixed pathological subtypes, and frontal
cortex as an overall less affected brain region in this disease. Basal ganglia regions, which would
be more severely affected in MSA-SND pathological subtype, were not available in most cases
and were therefore excluded. All MSA cases included in this study have been sequenced for the
entire coding region of the COQ2 gene [14], with no COQ2 variants associated with increased
risk of MSA being found in the entire cohort.
Brain tissue homogenization and CoQ10 measurement
Flash-frozen brain tissue (including similar amounts of grey and white matter) was homoge-
nized with a buffer that contained sucrose, EDTA and Tris (tris[hydroxymethyl]amino-
methane). The PH was 7.4 and the buffer was isotonic with the brain cells. Forty μL of the
homogenates were mixed with an internal standard (IS). The IS used was di-propoxy-CoQ10
which is a synthetic non-physiological ubiquinone. The IS was added to the brain homogenates
which were then vortex mixed, frozen in liquid nitrogen, and thawed twice to ensure maximal
release of cellular CoQ10. A solvent of hexane:ethanol (70:30% (v/v)) was added to the sample,
vortex mixed for 1 minute, and then centrifuged (5 min x 14,000 g, 25°C). Following centrifu-
gation, the upper organic layer containing lipophilic compounds including CoQ10 was
removed and evaporated to dryness. The sample was reconstituted in ethanol and loaded onto
a HPLC which was linked to a UV detector set at 275 nm. Ubiquinones, including CoQ10 have
a characteristic absorbance at 275 nm and the HPLC is calibrated with a quantified CoQ10 and
IS prior to analyzing the biological samples. This method is described in detail elsewhere [17].
Statistical analyses
Data were analyzed with SPSS (v.22). For both cerebellar and frontal cortex tissue, one-way
analysis of variance was performed to check for omnibus significant differences in the CoQ10
levels between the main diagnosis groups (MSA, CRB_ATX, CBD, DLB, IPD, and controls). A
post hoc Tukey HSD test was then used for pairwise comparisons. To reach a normal distribu-
tion of the CoQ10 levels, this variable was log-transformed prior to the abovementioned analy-
ses. These analyses were also performed considering subgroups for MSA (MSA-OPCA,
MSA-Mix and MSA-SND) and CRB_ATX (SCA, FRDA and other ataxias). Additionally, mul-
tinomial logistic regression was used to infer the magnitude of the association between the out-
come (diagnosis) and levels of CoQ10, corrected for potential confounding factors. Controls
were used as the reference group, except for comparisons between disease groups only; in this
case MSA was taken as the reference (Table 2). All models were adjusted for age (continuous),
gender (binomial), and post-mortem delay (continuous). For all the analyses performed, a p-
value<0.05 was considered significant.
Results
Wemeasured the CoQ10 levels in brain tissue from the cerebellum and the frontal cortex of
MSA, CBD, DLB, IPD, CRB_ATX, and elderly normal controls. Table 1 and Fig 1 show a sum-
mary of the results. The analysis of variance revealed an omnibus significant difference between
groups for the CoQ10 levels in the cerebellum [F(5,111) = 9.434, P< 0.001], but not in the
frontal cortex [F(4,88) = 1.976, NS]. Post hoc pairwise comparisons revealed that this differ-
ence is due to lower mean cerebellar CoQ10 levels in MSA when compared to all other diagno-
sis groups (Tukey test, P 0.002). The levels of CoQ10 were also mildly reduced in CRB_ATX
cases compared to controls (Table 1 and Fig 1), but this did not reach statistical significance.
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Following adjustment for potential confounders, we found a significant association between
the diagnosis and cerebellar CoQ10 levels (Table 2), with MSA presenting 3% less CoQ10 than
controls (Table 2A; OR = 0.97, P = 0.001) and less 3–4% than other disease groups (DLB, IPD,
CBD, and CRB_ATX; Table 2C; P 0.001). Given the findings in the cerebellum, we also sub-
divided MSA samples into the 3 pathological subtypes, and the CRB_ATX cases into spinocer-
ebellar ataxia (SCA), Friedreich’s ataxia (FRDA) and miscellaneous, and compared these
subgroups to controls (Tables 1 and 2B). Significantly lower levels of CoQ10 in the cerebellar
tissue were detected only in OPCA (OR = 0.95, P = 0.001) and the mixed type (OR = 0.96,
P = 0.005) MSA cases but not in SND cases when compared to controls (Table 2B and Fig 1B).
Within the cerebellar diseases (CRB_ATX), even though SCAs presented with the lowest levels
of CoQ10, this reduction was still not statistically significant when compared to the control
Table 2. Multinomial logistic regression estimates for the association between different diagnosis
groups and CoQ10 levels in human brain tissue.
A) All disease groups versus controls in the Cerebellum tissue
Diagnosis OR (95% CI) p value
MSA 0.97 (0.95–0.99) 0.001*
CBD 1.01 (1.00–1.02) 0.223
DLB 1.01 (1.00–1.02) 0.058
IPD 1.01 (1.00–1.02) 0.405
CRB_ATX 1.00 (0.99–1.01) 0.935
B) MSA and CRB_ATX subdivided into their respective subtypes versus controls in the Cerebellum
tissue
Diagnosis OR (95% CI) p value
MSA_SND 0.98 (0.96–1.01) 0.128
MSA_Mixed 0.96 (0.93–0.99) 0.005*
MSA_OPCA 0.95 (0.92–0.98) 0.001*
SCA 0.99 (0.97–1.01) 0.147
FRDA 1.01 (1.00–1.03) 0.062
other_ataxias 1.00 (0.97–1.02) 0.885
C) All other degenerative diseases versus MSA in the Cerebellum tissue
Diagnosis OR (95% CI) p value
CBD 1.04 (1.02–1.06) <0.001*
DLB 1.04 (1.02–1.06) <0.001*
IPD 1.04 (1.02–1.06) <0.001*
CRB_ATX 1.03 (1.01–1.05) 0.001*
D) All disease groups versus controls in the Frontal cortex tissue
Diagnosis OR(95% CI) p value
MSA 1.00 (1.00–1.01) 0.846
DLB 1.00 (1.00–1.01) 0.792
IPD 1.00 (1.00–1.01) 0.543
CRB_ATX 1.01 (1.00–1.01) 0.123
* and bold highlight significant values (p<0.05). All models were adjusted for age, gender, and post-
mortem delay.
Glossary: MSA = multiple system atrophy; MSA_SND = MSA striatonigral degeneration;
MSA_mixed = MSA mixed; MSA_OPCA = MSA olivopontocerebellar atrophy; CBD = corticobasal
degeneration; DLB = dementia with Lewy bodies; IPD = idiopathic Parkinson’s disease;
CRB_ATX = cerebellar ataxia; SCA = spinocerebellar ataxia; FRDA = Friedreich’s ataxia;
other_ataxias = other ataxias of miscellaneous origin; OR = odds ratio; 95% CI = 95% confidence interval.
doi:10.1371/journal.pone.0149557.t002
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Fig 1. A: Boxplot presenting CoQ10 levels in the cerebellum of MSA, CBD, DLB, IPD, CRB_ATX and controls. B: Boxplot presenting CoQ10 levels in the
cerebellum of MSA cases subdivided by pathological subtypes MSA_SND, MSA_mixed and MSA_OPCA, and also CRB_ATX cases subdivided into SCA,
FRDA and other_ATX. C: Boxplot presenting CoQ10 levels in the frontal cortex of MSA, DLB, IPD, CRB_ATX and controls. D: Boxplot presenting CoQ10
CoenzymeQ10 Is Decreased in MSA
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group (Table 2B). In the frontal cortex samples, we found no association between the diagnosis
and CoQ10 levels (Table 2D and Fig 1C).
Discussion
In this study we assessed the CoQ10 levels in the cerebellar and frontal cortices from MSA
patients and compared these results to elderly controls and samples from CBD, IPD, DLB and
CRB_ATX. This is the first study to have investigated the levels of CoQ10 in a large number of
pathologically confirmed MSA brain samples.
The unavailability of basal ganglia tissue as well as the relatively small sample size of some
of the disease groups (e.g. IPD) constitutes a limitation of this study. We found, however, sig-
nificantly decreased levels of CoQ10 in the cerebellar cortex of MSA patients, particularly of
the OPCA and mixed pathological subtypes, when compared to controls and all the other dis-
ease groups, but no differences were detected in the frontal cortex. Although the role of the
COQ2 variants as a cause of MSA is yet to be replicated, the specific and significant decrease of
CoQ10 in the cerebellar cortex of the MSA cohort, but not of cerebellar ataxias (CRB_ATX),
suggests that a perturbation in the CoQ10 biosynthetic pathway might be involved in the path-
ogenesis of MSA. In both cerebellar ataxias and MSA-OPCA and mixed Purkinje cell loss will
be present. Our results suggest that although CoQ10 reduction may reflect Purkinje cell loss it
is likely that other factors are contributing to the observed effect in MSA. More detailed studies
would be required to correlate the degree of Purkinje cell depletion with CoQ10 levels and elu-
cidate the cause and specificity of the CoQ10 biosynthesis impairment in MSA.
CoQ10 related pathways have been previously related to neurodegenerative diseases. The
mitochondrial respiratory chain complex I, of which CoQ10 is a cofactor [18, 19], has been
found to be dysfunctional in several neurodegenerative diseases, including IPD and progressive
supranuclear palsy (PSP). There is increasing evidence that impairment of mitochondrial func-
tion and oxidative damage are contributing factors to the pathophysiology of those diseases
[20–22]. Furthermore, reduced levels of CoQ10 in cerebral cortex and in lymphocytes of IPD
brains have been previously reported [20], and CoQ10 has been also proposed as a biomarker
of the antioxidant status in PD [21]. A recent study [23], which measured brain energy metabo-
lism in the basal ganglia of clinically diagnosed MSA-P cases, is not in support of mitochon-
drial dysfunction playing a primary role in the pathophysiology of MSA. Unfortunately, that
study did not include comparisons with the MSA-C clinical subtype to help understanding
whether this could be relevant to MSA when the cerebellum is the main affected brain region.
The treatment of MSA is limited and purely symptomatic. Whether the reduction in CoQ10
is linked specifically to the etiology of MSA or is related to the degree of neurodegeneration in
the cerebellum of MSA patients is uncertain. However, our results suggest that it may be worth
undertaking further studies to evaluate the efficacy of CoQ10 and/or idebenone in the treatment
of MSA given that these quinones are reported to be safe and well tolerated in patients [24, 25].
Conclusion
The role of COQ2 variants in the etiology of MSA remains debatable. However, our data sug-
gests that a deficiency in cerebellar CoQ10 status may be involved in the pathophysiology of
levels in the frontal cortex of MSA cases subdivided by pathological subtypes MSA_SND, MSA_mixed and MSA_OPCA, and also CRB_ATX cases
subdivided into SCA, FRDA and other_ATX. Each dot represents one individual, and dots beyond the boxplot whiskers represent outliers. Glossary:
MSA = multiple system atrophy; MSA_SND =MSA striatonigral degeneration; MSA_mixed = MSAmixed; MSA_OPCA =MSA olivopontocerebellar atrophy;
CBD = corticobasal degeneration; DLB = dementia with Lewy bodies; IPD = idiopathic Parkinson’s disease; CRB_ATX = cerebellar ataxia;
SCA = spinocerebellar ataxia; FRDA = Friedreich’s ataxia; other_ATX = other ataxias of miscellaneous origin.
doi:10.1371/journal.pone.0149557.g001
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MSA. More work is required before we can elucidate whether this consists of a primary
involvement in the pathogenesis of MSA or is a secondary finding due to neurodegeneration.
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